Health Care · Biological Products, (No Diagnostic Substances)

KYMR Kymera Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1815442109 filings
Russell 2000

KYMR at a glance

Kymera Therapeutics, Inc. (KYMR, SEC CIK 1815442) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Kymera Therapeutics, Inc. (KYMR) reported revenue of $39.2 million (down 16.7% from FY2024) and a net loss of $311.4 million. Diluted EPS was -$3.69.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Kymera Therapeutics, Inc. (KYMR) shares worth $3.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Mainolfi Nello on October 1, 2026 of 3,525 shares at $111.44 per share.
  • In the last 90 days, KYMR insiders reported 0 open-market purchases ($0) and 9 open-market sales ($4.2M) on Form 4, a net sale of $4.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$39.2M
−16.7% vs prior year
Insiders · 90 days
0 buys · 9 sells
Net −$4.2M
13F holders
29 funds
$3.2B · −3 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Clinical-stage biopharma specializing in targeted protein degradation (TPD) oral small molecules for immunology and serious diseases
  • New products: Initiated Phase 2b trials for KT-621 (oral STAT6 degrader) in atopic dermatitis and asthma; Phase 1 trial started for KT-579 (oral IRF5 degrader)
  • Strategic shifts: Expanded collaborations with Sanofi for IRAK4 degrader advancing to clinical testing in 2026 and new agreement with Gilead for molecular glue degraders targeting CDK2
  • Quantitative highlight: KT-621 Phase 1b trial showed 98% median STAT6 degradation in blood, 62-74% reduction in Type 2 biomarkers, and up to 63% improvement in EASI scores by Day 29
  • Noteworthy fact: First demonstration of IL-31 and FeNO reductions in AD patients with oral STAT6 degradation therapy, potentially matching injectable biologics' efficacy

Risk Factors

  • Regulatory risk: FDA approval timing and success uncertainty for STAT6, IRF5, and IRAK4 programs affecting clinical development and commercialization
  • Macroeconomic risk: Potential capital exhaustion before 2029 despite $1.62B cash, risking delays in R&D and clinical trials
  • Operational risk: Dependency on third-party manufacturers and CROs for supply of clinical trial materials and manufacturing
  • Competitive risk: Collaboration with Sanofi and Gilead required to advance programs, risk if partners prioritize other pipeline assets
  • Financial risk: Net losses of $311.4M in 2025 with accumulated deficit $1.07B, requiring substantial future financings to sustain operations

Management Discussion & Analysis

  • No forward-looking guidance or management outlook mentioned

AI summary of the KYMR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $0 vs $2.8M YoY, down $2.8M
  • Net loss $132.0M vs $82.2M YoY, operating loss $147.2M vs $92.5M
  • STAT6 highest R&D investment $52.0M vs $17.4M, up $34.7M
  • Cash used in operations $220.8M, financing provided $258.8M, net cash increase $16.8M
  • Cash, equivalents and marketable securities $1.646B, funding expected into 2029 but additional capital required

Risk Factors

  • Newly added BIOSECURE Act risk: Section 851 enacted December 18, 2025, potentially restricting provider relationships and delaying development
  • Regulatory risk: FDA staffing cuts, shutdowns, and policy changes could delay IND reviews and product approvals
  • Clinical risk: STAT6 and IRF5 programs remain in early clinical development, increasing failure and timeline uncertainty
  • Competitive risk: Sanofi, Johnson & Johnson, and Gilead announced STAT6 partnerships
  • Financial risk: $1,646 million in cash and securities expected to fund operations into 2029, subject to inaccurate assumptions

AI summary of the KYMR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Quarterly results announced for period ended September 30, 2026
  • Full financial details and management commentary in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $132.0M, or $1.32 per share, versus $82.2M, reflecting sharply higher pipeline investment
  • R&D expense $128.5M, up from $74.1M, primarily supporting STAT6, discovery programs and organizational growth
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Kymera reported financial results for quarter ended June 30, 2026
  • Full results and management commentary provided in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q2 collaboration revenue $65.0M, including $45M from Gilead and $20M Sanofi milestone payments
  • BROADEN2 AD enrollment completed nearly six months early, pulling expected KT-621 data forward to year-end 2026
Filed Jul 27, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jared Gollob, M.D. resigned as Chief Medical Officer effective July 27, 2026
  • Continued advisor role through December 31, 2026 supports transition continuity

Item EX-99.1: Item EX-99.1

  • Terence Rooney appointed Chief Medical Officer to lead global clinical development and Kymera’s oral immunology portfolio
  • Rooney brings immunology development experience from Johnson & Johnson, Eli Lilly and Roche

Item 7.01: Regulation FD Disclosure

  • Dr. Rooney appointed Chief Medical Officer, changing leadership of Kymera’s clinical development function
  • Dr. Gollob retired as Chief Medical Officer, creating a senior medical leadership transition

AI summaries of KYMR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KYMR

Don't miss the next KYMR filing

  • Alerts as it files. A push when KYMR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KYMR, by share count.
  • Ask anything. An AI agent that reads every KYMR filing and answers with sources.

KYMR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Mainolfi NelloMOct 1, 2026$2.08
Mainolfi NelloSellOct 1, 2026$111.44
Mainolfi NelloSellOct 1, 2026$112.42
Mainolfi NelloSellOct 1, 2026$113.24
Mainolfi NelloSellOct 1, 2026$114.43
Mainolfi NelloSellOct 1, 2026$115.40
Mainolfi NelloSellOct 1, 2026$116.12
Mainolfi NelloMOct 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$78.6M$47.1M$39.2M
Operating Income--$261.6M-$349.4M
Net Income-$147.0M-$223.9M-$311.4M
Op. Margin--555.8%-891.1%
Net Margin-187.0%-475.6%-794.0%
Balance Sheet
Total Assets-$978.0M$1.7B
Equity-$835.6M$1.6B
ROE--26.8%-19.7%
Per Share
EPS$-2.52$-2.98$-3.69
Cash Flow
Operating CF--$194.5M-$232.9M
CapEx$34.5M$12.8M$1.4M

Source: XBRL data in Kymera Therapeutics, Inc. (KYMR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KYMR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KYMR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$3.23B
Q2 202632$4.51B
Q1 202628$2.96B
Q4 202525$2.55B
Q3 202527$1.55B
Q2 202526$1.19B
Q1 202522$402.0M
Q4 202421$562.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KYMR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
4Oct 1, 2026--
4Sep 4, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
8-KJul 27, 2026Analysis-
4Jul 27, 2026--
4Jul 7, 2026--
4Jul 2, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 26, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
8-KJun 25, 2026Analysis-
4Jun 25, 2026--
4Jun 25, 2026--

Related Health Care companies

All Health Care →

KYMR SEC filings: frequently asked questions

Are KYMR insiders buying or selling?

In the last 90 days, Kymera Therapeutics, Inc. (KYMR) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $4.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold KYMR stock?

As of September 30, 2026, the largest Kymera Therapeutics, Inc. (KYMR) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($975.5 million), BlackRock ($651.2 million), Vanguard Capital Management LLC ($340.3 million), Vanguard Portfolio Management LLC ($333.0 million), State Street Corp ($288.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was KYMR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Kymera Therapeutics, Inc. (KYMR) reported revenue of $39.2 million (down 16.7% from FY2024) and a net loss of $311.4 million. Diluted EPS was -$3.69. The figures come from the XBRL data in the 10-K.

What are the main risks in KYMR's latest 10-K?

In the 10-K filed February 26, 2026, Kymera Therapeutics, Inc. (KYMR) flagged: Regulatory risk: FDA approval timing and success uncertainty for STAT6, IRF5, and IRAK4 programs affecting clinical development and commercialization. Macroeconomic risk: Potential capital exhaustion before 2029 despite $1.62B cash, risking delays in R&D and clinical trials. (AI summary of the Risk Factors section.)

What did KYMR report in its latest 8-K?

Kymera Therapeutics, Inc. (KYMR) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Quarterly results announced for period ended September 30, 2026.

What are the latest KYMR SEC filings?

Kymera Therapeutics, Inc. (KYMR) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on October 1, 2026.

What is KYMR's SEC CIK number?

Kymera Therapeutics, Inc. (KYMR)'s SEC Central Index Key (CIK) is 1815442. EDGAR lists every KYMR filing under that number.

Ask anything about KYMR

The research agent reads KYMR's filings, financials, insider trades and 13F holders, then answers with sources.